Donislecel is an allogeneic pancreatic islets cellular therapy indicated for the treatment of type 1 diabetes. The primary mechanism of action of donislecel is attributed to the secretion of insulin and other pancreatic hormones from infused allogeneic islet cells to mimic endogenous glucose control and homeostasis.
- Mechanism
- Curator reviewed · 2 references
As donislecel-jujn is a pancreatic islet cellular therapy, its mechanism of action stems from the secretion of insulin by the β- cells in the transplanted islet cells.
Pancreatic islets regulate blood glucose levels through the secretion of multiple hormones in response to increases or decreases in blood glucose. Endocrine cells within pancreatic islets release insulin, glucagon, somatostatin, pancreatic peptide, and ghrelin. Insulin stimulates glucose uptake by peripheral tissues; glucagon mobilizes glucose from the liver into circulation; somatostatin inhibits both α- and β-cell secretions; pancreatic peptide inhibits pancreatic exocrine secretion, and ghrelin inhibits insulin secretion.
- Primary indication
- Donislecel-jujn is an allogeneic pancreatic islet cellular therapy indicated for the treatment of adults with Type 1 diabetes who are unable to approach target HbA1c because of current repeated episodes of severe hypoglycemia despite intensive...Curator reviewed · 1 structured indication
- First approval
- United States, 2023
- Brand names
Resolves to
What you can answer from here — as of April 02, 2025
Which other approved drugs treat the same conditions as Donislecel, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account